Patents by Inventor Peter R Baum
Peter R Baum has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230062712Abstract: The disclosure provides conjugates of anti-ASGR1 antibodies or antigen binding fragments thereof to a myeloid cell agonist, compositions comprising the conjugates, and methods of treating liver viral infections with the conjugates. The disclosure also provides for anti-ASGR1 antibodies or antigen binding fragments thereof and methods for using the antibodies or antigen binding fragments thereof in treating liver viral infections.Type: ApplicationFiled: December 9, 2021Publication date: March 2, 2023Inventors: Peter R. Baum, Robert Dubose, Valerie Odegard, Philip Tan, Peter A. Thompson, Sean W. Smith, Brenda Stevens
-
Patent number: 11541126Abstract: The disclosure provides conjugates of anti-ASGR1 antibodies or antigen binding fragments thereof to a myeloid cell agonist, compositions comprising the conjugates, and methods of treating liver viral infections with the conjugates. The disclosure also provides for anti-ASGR1 antibodies or antigen binding fragments thereof and methods for using the antibodies or antigen binding fragments thereof in treating liver viral infections.Type: GrantFiled: July 1, 2021Date of Patent: January 3, 2023Assignee: SILVERBACK THERAPEUTICS, INC.Inventors: Peter R. Baum, Robert Dubose, Valerie Odegard, Philip Tan, Peter A. Thompson, Sean W. Smith, Brenda Stevens
-
Publication number: 20220105196Abstract: The present disclosure provides conjugates of anti-Nectin-4 antibodies or antigen binding fragments thereof to a myeloid cell agonist, compositions comprising the conjugates, and methods of treating cancer with the conjugates. The present disclosure also provides for anti-Nectin-4 antibodies or antigen binding fragments thereof and method for using the antibodies or antigen binding fragments thereof in treating cancer.Type: ApplicationFiled: October 4, 2021Publication date: April 7, 2022Inventors: Peter R. Baum, Robert Dubose, Valerie Odegard, Brenda Stevens, Philip Tan
-
Patent number: 11179473Abstract: The present disclosure provides conjugates of anti-Nectin-4 antibodies or antigen binding fragments thereof to a myeloid cell agonist, compositions comprising the conjugates, and methods of treating cancer with the conjugates. The present disclosure also provides for anti-Nectin-4 antibodies or antigen binding fragments thereof and method for using the antibodies or antigen binding fragments thereof in treating cancer.Type: GrantFiled: February 19, 2021Date of Patent: November 23, 2021Assignee: Silverback Therapeutics, Inc.Inventors: Peter R. Baum, Robert Dubose, Valerie Odegard, Brenda Stevens, Philip Tan
-
Publication number: 20210275683Abstract: The present disclosure provides conjugates of anti-Nectin-4 antibodies or antigen binding fragments thereof to a myeloid cell agonist, compositions comprising the conjugates, and methods of treating cancer with the conjugates. The present disclosure also provides for anti-Nectin-4 antibodies or antigen binding fragments thereof and method for using the antibodies or antigen binding fragments thereof in treating cancer.Type: ApplicationFiled: February 19, 2021Publication date: September 9, 2021Inventors: Peter R. Baum, Robert Dubose, Valerie Odegard, Brenda Stevens, Philip Tan
-
Publication number: 20210130473Abstract: Various conjugates and compositions thereof are disclosed for use in the treatment of a liver disease, such as liver cancer and liver fibrosis. The compositions comprise conjugates, wherein the conjugates are comprised of an antibody or antibody construct specific for ASGR1 or ASGR2 attached to a TGF?R1 inhibitor via a linker. Additionally provided are the methods of preparation of the conjugates and compositions thereof.Type: ApplicationFiled: October 9, 2020Publication date: May 6, 2021Inventors: Peter R. BAUM, Robert DUBOSE, Valerie ODEGARD, Philip TAN, Peter A. THOMPSON, Sean W. SMITH, Brenda STEVENS
-
Patent number: 8674078Abstract: The invention provides isolated BTL-II proteins, nucleic acids, antibodies, antagonists, and agonists and methods of making and using the same. Diagnostic, screening, and therapeutic methods using the compositions of the invention are provided. For example, the compositions of the invention can be used for diagnosis and treatment of inflammatory bowel diseases and for enhancing a mucosal immune response to an antigen.Type: GrantFiled: April 10, 2012Date of Patent: March 18, 2014Assignee: Immunex CorporationInventors: Peter R. Baum, Sabine S. Escobar, Joanne L. Viney
-
Patent number: 8383106Abstract: Immunoglycoproteins, including antibodies, with improved ADCC and altered glycosylation patterns are provided. Also provided are cell culturing methods and media for producing such immunoglycoproteins, and therapeutic uses of such immunoglycoproteins.Type: GrantFiled: October 21, 2010Date of Patent: February 26, 2013Assignee: Emergent Product Development Seattle, LLCInventors: Erik S. Espling, Peter A. Thompson, Peter R. Baum
-
Publication number: 20120258097Abstract: The invention provides isolated BTL-II proteins, nucleic acids, antibodies, antagonists, and agonists and methods of making and using the same. Diagnostic, screening, and therapeutic methods using the compositions of the invention are provided. For example, the compositions of the invention can be used for diagnosis and treatment of inflammatory bowel diseases and for enhancing a mucosal immune response to an antigen.Type: ApplicationFiled: April 10, 2012Publication date: October 11, 2012Applicant: Immunex CorporationInventors: Peter R. BAUM, Sabine S. Escobar, Joanne L. Viney
-
Publication number: 20120121505Abstract: The present application provides novel binding proteins, including human binding proteins that specifically bind to the human ErbB2.Type: ApplicationFiled: January 12, 2012Publication date: May 17, 2012Inventors: Davinder Singh Gill, Laird Bloom, Maximillian T. Follettie, Fionnuala McAleese, Sreekumar Kodangattil, John Francis DiJoseph, Nitin K. Damle, Peter R. Baum, Peter A. Thompson, John C. Kumer, Alan F. Wahl, Paul A. Algate, Sateesh Kumar Natarajan
-
Patent number: 8173603Abstract: The invention provides isolated BTL-II proteins, nucleic acids, antibodies, antagonists, and agonists and methods of making and using the same. Diagnostic, screening, and therapeutic methods using the compositions of the invention are provided. For example, the compositions of the invention can be used for diagnosis and treatment of inflammatory bowel diseases and for enhancing a mucosal immune response to an antigen.Type: GrantFiled: March 3, 2010Date of Patent: May 8, 2012Assignee: Immunex CorporationInventors: Peter R. Baum, Sabine S. Escobar, Joanne L. Viney
-
Publication number: 20110256125Abstract: Immunoglycoproteins, including antibodies, with improved ADCC and altered glycosylation patterns are provided. Also provided are cell culturing methods and media for producing such immunoglycoproteins, and therapeutic uses of such immunoglycoproteins.Type: ApplicationFiled: October 21, 2010Publication date: October 20, 2011Applicant: TRUBION PHARMACEUTICALS, INC.Inventors: Erik S. ESPLING, Peter A. THOMPSON, Peter R. BAUM
-
Publication number: 20100330104Abstract: The invention provides isolated BTL-II proteins, nucleic acids, antibodies, antagonists, and agonists and methods of making and using the same. Diagnostic, screening, and therapeutic methods using the compositions of the invention are provided. For example, the compositions of the invention can be used for diagnosis and treatment of inflammatory bowel diseases and for enhancing a mucosal immune response to an antigen.Type: ApplicationFiled: March 3, 2010Publication date: December 30, 2010Applicant: Immunex CorporationInventors: Peter R. Baum, Sabine S. Escobar, Joanne L. Viney
-
Publication number: 20100168399Abstract: The invention is directed to B7L-1 as a purified and isolated protein, the DNA encoding the B7L-1, host cells transfected with cDNAs encoding B7L-1 and processes for preparing B7L-1 polypeptides.Type: ApplicationFiled: February 26, 2010Publication date: July 1, 2010Applicant: Immunex CorporationInventor: Peter R. Baum
-
Patent number: 7709618Abstract: The invention provides isolated BTL-II proteins, nucleic acids, antibodies, antagonists, and agonists and methods of making and using the same. Diagnostic, screening, and therapeutic methods using the compositions of the invention are provided. For example, the compositions of the invention can be used for diagnosis and treatment of inflammatory bowel diseases and for enhancing a mucosal immune response to an antigen.Type: GrantFiled: June 8, 2007Date of Patent: May 4, 2010Assignee: Immunex CorporationInventors: Peter R Baum, Sabine S Escobar, Joanne L Viney
-
Publication number: 20090304590Abstract: The present application provides novel binding proteins, including human binding proteins that specifically bind to the human ErbB2.Type: ApplicationFiled: October 27, 2008Publication date: December 10, 2009Applicants: Wyeth, Trubion Pharmaceuticals, Inc.Inventors: Davinder Singh Gill, Laird Bloom, Maximillian T. Follettie, Fionnuala McAleese, Sreekumar Kodangattil, John Francis DiJoseph, Nitin K. Damle, Peter R. Baum, Peter A. Thompson, John C. Kumer, Alan F. Wahl, Paul A. Algate, Sateesh Kumar Natarajan
-
Publication number: 20090258005Abstract: The present application provides novel binding proteins, including human binding proteins that specifically bind to the human ErbB2.Type: ApplicationFiled: May 29, 2008Publication date: October 15, 2009Applicants: Trubion Pharmaceuticals Inc., WyethInventors: Davinder Gill, Fionnuala McAleese, Peter A. Thompson, Peter R. Baum, Paul A. Algate
-
Publication number: 20090226417Abstract: This invention relates to B7-H1.2 and Butryophilin 2/3, new members of the human B7 polypeptide family, methods of making such polypeptides, and to methods of using them to treat immunological conditions and to identify compounds that alter the activities of these human B7 polypeptides.Type: ApplicationFiled: August 8, 2007Publication date: September 10, 2009Applicant: Immunex CorporationInventors: Peter R. Baum, Robert F. DuBose, Steven R. Wiley
-
Publication number: 20090142801Abstract: The invention provides isolated BTL-II proteins, nucleic acids, antibodies, antagonists, and agonists and methods of making and using the same. Diagnostic, screening, and therapeutic methods using the compositions of the invention are provided. For example, the compositions of the invention can be used for diagnosis and treatment of inflammatory bowel diseases and for enhancing a mucosal immune response to an antigen.Type: ApplicationFiled: June 8, 2007Publication date: June 4, 2009Applicant: IMMUNEX CORPORATIONInventors: Peter R. BAUM, Sabine S. ESCOBAR, Joanne L. VINEY
-
Publication number: 20090041765Abstract: Immunoglycoproteins, including antibodies, with improved ADCC and altered glycosylation patterns are provided. Also provided are cell culturing methods and media for producing such immunoglycoproteins, and therapeutic uses of such immunoglycoproteins.Type: ApplicationFiled: April 11, 2008Publication date: February 12, 2009Applicant: TRUBION PHARMACEUTICALS, INC.Inventors: Erik S. Espling, Peter A. Thompson, Peter R. Baum
